Employees: 551
Size Assure Tech (Hangzhou) (688075.SS) is a China Health Care company (Medical Specialties) with a market value of $508M, the 3671st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥26.64 on 18 Nov 2026.
Performance Over six months the shares fell 26.9%, against -16.1% for the median peer and -20.0% for the China market (cap-weighted) — 7th lowest of 21 in its peer set.
Growth Revenue fell 9.5% over the last twelve months (peer median +7.0%); the operating margin is -7.9% (peer median 3.5%).
Valuation It trades at 5.4× enterprise value to sales against a peer median of 2.4× (6th most expensive of 19).
Price implies For today's price to make sense, revenue must grow about 31% a year for seven years (Req g). Recent delivered growth is -19%, so the hurdle is +49 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 8.2 points below its cost of capital (8.7% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥419M | CN¥427M | CN¥537M | CN¥495M | CN¥6.12B |
| Revenue growth | — | -20% | +9% | -92% | — |
| Gross profit | CN¥225M | CN¥147M | CN¥185M | CN¥181M | CN¥4.55B |
| EBITDA | n/a | CN¥19.5M | CN¥38.3M | CN¥52.9M | CN¥3.23B |
| Net income | -CN¥25.4M | CN¥69.4M | CN¥192M | CN¥142M | CN¥3.04B |
| Free cash flow | CN¥144M | CN¥26.8M | CN¥111M | -CN¥840M | CN¥3.18B |
| Capital expenditure | CN¥77.4M | CN¥95.6M | CN¥107M | CN¥337M | CN¥627M |
| Total debt | CN¥189M | CN¥94.5M | CN¥82.0M | CN¥118M | CN¥212M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688075.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -9.6% | -3.8% | 4th lowest of 21 |
| 6-month return | -26.9% | -16.1% | 7th lowest of 21 |
| Distance from 52-week high | -40.8% | -37.7% | 11th highest of 21 |
| Revenue growth (TTM) | -9.5% | +7.0% | 2nd lowest of 21 |
| Operating margin | -7.9% | 3.5% | 6th lowest of 21 |
| EV / Sales | 5.4× | 2.4× | 6th most expensive of 19 |
| Growth the price implies (Req g, 7 yrs) | 30.8% | 5.3% | 2nd most demanding of 11 |
| Growth delivered (Del g) | -18.6% | +4.6% | lowest of 11 |
| Hurdle (Req g minus delivered) | +49.4 pp | +1.6 pp | 2nd most demanding of 11 |
| ROIC minus cost of capital | -8.2 pp | -1.3 pp | 6th lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Assure Tech (Hangzhou) 688075.SS | China | $508M | -27% | -9% | -8% | 5.4× | 30.8% | -18.6% |
| Anteris Technologies Global AVR | United States | $508M | -40% | +9% | -4,880% | 125.0× | n/a | n/a |
| Shofu 7979.T | Japan | $510M | +32% | +9% | 14% | 1.6× | n/a | n/a |
| Guangdong Hybribio Biotech 300639.SZ | China | $511M | -18% | -7% | 4% | 3.9× | 0.4% | -13.2% |
| Zhejiang Orient Gene Biotech 688298.SS | China | $500M | -27% | +18% | -60% | 1.6× | n/a | n/a |
| Nanjing Vishee Medical Technology 688580.SS | China | $499M | -43% | +7% | 24% | 5.3× | 20.1% | +4.2% |
| Anbio Biotechnology NNNN | United States | $518M | -89% | +10% | 67% | n/a | n/a | n/a |
| MedicalSystem Biotechnology 300439.SZ | China | $518M | -9% | +14% | 2% | 1.5× | 6.0% | -7.7% |
| medmix MEDX.SW | Switzerland | $494M | +11% | -7% | 6% | 1.4× | 4.5% | +5.0% |
| Zhejiang Starry Pharmaceutical 603520.SS | China | $491M | -44% | +9% | 3% | 2.2× | n/a | n/a |
| AVITA Medical RCEL | United States | $529M | +290% | +17% | -34% | 6.7× | n/a | n/a |
| Myriad Genetics MYGN | United States | $530M | +45% | -3% | -13% | 0.8× | n/a | n/a |
| Wuhan Easy Diagnosis Biomedicine 002932.SZ | China | $485M | -14% | -9% | -51% | n/a | n/a | n/a |
| Jin Medical International ZJYL | United States | $532M | +47% | -14% | 2% | 26.5× | n/a | n/a |
| Hangzhou Alltest Biotech 688606.SS | China | $484M | -20% | 0% | 13% | 1.3× | -6.5% | -4.3% |
| Medprin Regenerative Medical Technologies 301033.SZ | China | $482M | -14% | +23% | 31% | 7.0× | 4.3% | +24.4% |
| Guangdong Biolight Meditech 300246.SZ | China | $478M | -35% | +7% | -8% | 3.1× | 55.3% | -4.7% |
| CellaVision CEVI.ST | Sweden | $477M | +64% | +2% | 23% | 6.1× | 7.1% | +10.0% |
| AngioDynamics ANGO | United States | $476M | -4% | +8% | -6% | 1.4× | n/a | n/a |
| Zhejiang Gongdong Medical Technology 605369.SS | China | $542M | -21% | +6% | 9% | 2.6× | 10.2% | +6.5% |
| WELL LEAD MEDICAL 603309.SS | China | $473M | -22% | +1% | 15% | 2.0× | -5.9% | +7.7% |